A REVIEW ON QUALITY BY DESIGN APPROACH (QBD) AND IT’S BENEFITS
No Thumbnail Available
Author/Creator ORCID
Date
2024-08-31
Type of Work
Department
Program
Citation of Original Publication
Krishna, Ambati Vamsi, Paradeshi Mounika, G. Vedavathi Sai, and Kannedari Venkatesh. “A REVIEW ON QUALITY BY DESIGN APPROACH (QBD) AND IT’S BENEFITS,” International Journal of Pharmacognosy 11, no. 8 (August 31, 2024): 414-420. https://ijpjournal.com/bft-article/a-review-on-quality-by-design-approach-qbd-and-its-benefits/.
Rights
This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Subjects
Abstract
The newest approach in pharmaceutical production linked to quality is called Quality by Design (QbD). To guarantee that premium-grade pharmaceuticals are produced, Pharmaceutical Quality by Design, or QbD, is discussed in this article. A description of Quality by Design is provided along with a list of its constituent parts. Every unit activity has its own set of quality metrics and characteristics. The use of Quality by Design and its associated measures can yield significant benefits for pharmaceutical goods. The foundation of pharmaceutical R&D is high-quality drugs and the procedures used in their production. A product’s quality cannot be easily verified because this paper just summarises the product’s quality profile and the most important components of Quality by Design. Quality by design (QbD) and end-product testing are two ways to compare the quality of various goods. Quality by Design is based on the ICH Guidelines. ICH guidelines apply to the development of medications and the application of quality control methods. The research and manufacturing of pharmaceuticals might profit from Quality by Design (QbD). As the product develops and is designed, it is crucial to determine the desired product performance report under these ideas. The TPP, QTPP, and CQA stand for target product profile, quality target product profile, and critical quality characteristics. to identify and regulate sources of changeability and to understand how key material attributes (CAM) and critical process parameters (CPP) of the raw material affect the CQAs. Quality-based drug development (QbD) can provide valuable insights for the design, development, and manufacturing of pharmaceutical products. The present overview discusses the historical context, fundamentals of the QbD methodology, and regulatory requirements. The method’s aim, the experiment’s design, and the risk assessment are all explained in depth for the QbD aspects. The ICH Guidelines provide the basis of Quality by Design. The ICH Guidelines Q8, Q9, and Q10 for pharmaceutical quality systems, quality risk management, and pharmaceutical development, respectively, serve as its foundation. It also provides information on applying Quality by Design to the creation and production of medicines.